Condition: Acute Spinal Cord Injury (SCI) · Sponsor: Kringle Pharma, Inc.
This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.
This description comes directly from the study's public registry record.
Daichika Hayata · '+81-6-7653-6728 · hayata@kringle-pharma.com
Yurika Abe · +81-6-7653-6728 · y.abe@kringle-pharma.com
Always discuss trial participation with your own doctor first.
| Japan Organization for Occupational Health and Safety Comprehensive Spinal Cord Injuries Center | Iizuka, Fukuoka, Japan | — |
| Japan Organization for Occupational Health and Safety Hokkaido Spinal Cord Injury Center | Bibai, Hokkaido, Japan | — |
| National Hospital Organization Murayama Medical Center | Musashimurayama, Tokyo, Japan | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07722962